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Abstract 
Background: Children with type 1 diabetes (T1D) are at higher risk of early adult-onset cardiovascular disease. We 
assessed cardiovascular structure and function in adolescents with T1D compared with healthy controls and the rela-
tionships between peripheral vascular function and myocardial parameters.
Methods and results: 199 T1D [14.4 ± 1.6 years, diabetes duration 6.2 (2.0–12.8) years] and 178 controls 
(14.4 ± 2.1 years) completed endothelial function by flow mediated vasodilatation (FMD), arterial stiffness using 
pulse wave velocity (PWV) along with M-mode, pulse wave and tissue Doppler, and myocardial deformation echo-
cardiographic imaging. Systolic (113 ± 10 vs. 110 ± 9 mmHg; p = 0.0005) and diastolic (62 ± 7 vs. 58 ± 7 mmHg; 
p < 0.0001) blood pressures, carotid femoral PWV and endothelial dysfunction measurements were increased in T1D 
compared with controls. Systolic and diastolic left ventricular dimensions and function by M-mode and pulse wave 
Doppler assessment were not significantly different. Mitral valve lateral e’ (17.6 ± 2.6 vs. 18.6 ± 2.6 cm/s; p < 0.001) 
and a’ (5.4 ± 1.1 vs. 5.9 ± 1.1 cm/s; p < 0.001) myocardial velocities were decreased and E/e’ (7.3 ± 1.2 vs. 6.7 ± 1.3; 
p = 0.0003) increased in T1D. Left ventricular mid circumferential strain (−20.4 ± 2.3 vs. −19.5 ± 1.7 %; p < 0.001) was 
higher, whereas global longitudinal strain was lower (−19.0 ± 1.9 vs. −19.8 ± 1.5 % p < 0.001) in T1D.
Conclusions: Adolescents with T1D exhibit early changes in blood pressure, peripheral vascular function and left 
ventricular myocardial deformation indices with a shift from longitudinal to circumferential shortening. Longitudinal 
follow-up of these changes in ongoing prospective trials may allow detection of those most at risk for cardiovascular 
abnormalities including hypertension that could preferentially benefit from early therapeutic interventions.
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Background
The development of abnormal ventricular function in 
diabetes is multifactorial and has been attributed to met-
abolic disturbances, renal impairment, myocardial fibro-
sis, small vessel disease, cardiac autonomic neuropathy, 
and insulin resistance [1, 2]. In adults longer duration 
of diabetes is associated with impairment of systolic and 
diastolic function [3]. Glycemic changes and lipid abnor-
malities are associated with early vascular changes in 
children with T1D [4], but less is known in regard to how 
these metabolic disturbances affect myocardial structure 
and function. Given that adolescence is a critical period 
associated with onset and progression of vascular com-
plications and poor glycemic control, it is important to 
evaluate central cardiac and peripheral vascular changes.
Diabetes has long been known to be a major risk fac-
tor for the development of cardiovascular disease [5]. 
Consequently, children with type 1 diabetes (T1D) are at 
higher risk of early adult-onset cardiovascular disease [6]. 
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In adults increased morbidity and mortality have been 
observed due to coronary, cerebrovascular, and periph-
eral arterial disease [7], and early vascular changes have 
been shown to be present from childhood [8, 9]. To date, 
however, little is known about the evolution of early car-
diac structural and functional abnormalities in children 
with T1D, as previous echocardiographic studies have 
shown variable differences in left ventricular (LV) geom-
etry, mass and function [10–15]. More recently, myocar-
dial deformation imaging has been shown to detect early 
changes in LV myocardial mechanics in children and 
adolescents with T1D prior to changes in ejection frac-
tion [16].
Accordingly, our aim was to evaluate cardiovascular 
structure and function in adolescents with T1D com-
pared with healthy controls and to assess the relation-
ships between these peripheral vascular and myocardial 
parameters with clinical parameters in patients with T1D.
Methods
Study population
Patients were recruited from the longitudinal, observa-
tional, non-interventional arm of the adolescent type 1 
diabetes cardio-renal intervention trial (AdDIT) from 
clinical sites in the Greater Toronto Area. In brief, the 
non-randomized low-risk arm of AdDIT is a 4-year 
observational/natural history study, following adoles-
cents at low and middle risk of developing microal-
buminuria (EudraCT Number: 2007-001039-72) [17]. 
High-risk adolescents are recruited into the AdDIT inter-
ventional study (http://www.clinicaltrials.gov/ct2/show/
NCT01581476), which was designed to examine the 
effect of angiotensin converting enzyme inhibitors and 
statins on renal, retinal and cardiovascular endpoints. 
Our study did not include participants involved in the 
intervention trial; however, as an ancillary component of 
non-randomized low-risk arm of AdDIT we also included 
high-risk subjects who chose not to enter the AdDIT 
intervention study. All analyses in this manuscript were 
performed using biological specimens and data collected 
from subjects enrolled in the observational and ancillary 
arm of AdDIT, specifically baseline data from the study 
obtained at Greater Toronto Area sites.
Patients with uncomplicated T1D were recruited from 
endocrinology clinics at The Hospital for Sick Children, 
Credit Valley Hospital and Markham–Stouffville in the 
Greater Toronto Area (Ontario, Canada), and inclusion/
exclusion criteria have been described elsewhere [18]. 
Healthy controls were recruited through local advertise-
ments. The Hospital for Sick Children was the primary 
site of recruitment and also coordinated recruitment 
at the secondary sites (REB# 1000012240). The Hos-
pital for Sick Children Research Ethics Board, Credit 
Valley Hospital Ethics Forum and Markham–Stouffville 
Research Ethics Board approved the protocol and the 
consent procedure. Written informed consent was 
obtained from the legal guardian/next of kin/caretakers 
of minors aged 15 and younger, while the minors pro-
vided assent. All subjects, aged 16 and older with capac-
ity to understand the study information, gave  complete 
written and informed consent to participate in the study.
Control subjects were recruited as similar aged healthy 
volunteers, who were not on any vasoactive medications, 
had no previous history of familial hyperlipidemia, dia-
betes, obesity, hypertension, or any other significant 
cardiac, renal or systemic disease and normal cardiac 
anatomy and function by screening echocardiogram [18].
Clinical assessment
For adolescents with T1D, data on chronological age, age 
at diabetes onset, and duration of diabetes were collected. 
For all subjects, height was measured by a wall-mounted 
stadiometer and weight by electronic scales and resting 
heart rate and right brachial blood pressure was meas-
ured using an age-appropriate cuff and averaging three 
readings with an automated DINAMAP® sphygmoma-
nometer (Critikon, Tampa, Florida, USA). Systolic and 
diastolic blood pressures were also converted to z-scores 
for age, sex and height [19]. For all T1D and a subgroup 
of 65 controls that underwent the same baseline clini-
cal assessment, fasting blood samples were collected for 
blood glucose, HbA1c measurements and lipid profiles 
[total cholesterol, HDL (high-density lipoprotein) cho-
lesterol, LDL (low-density lipoprotein) cholesterol and 
triglycerides] and serum cystatin C was used to estimate 
glomerular filtration rate, as previously described [20].
Echocardiographic assessment
Using a Vivid 7 ultrasound system (GE, General Elec-
tric Corp, Wisconsin, USA) a standardized functional 
imaging protocol was performed according to pub-
lished guidelines [21], and using methods as previously 
described by our group [22–24].
LV end-diastolic and end-systolic dimensions and 
thicknesses were measured using M-mode in the par-
asternal short-axis view. LV mass indexed to body sur-
face area (BSA), shortening fraction, ejection fraction 
and heart rate-corrected velocity of circumferential fiber 
shortening were calculated.
Pulse wave Doppler images were acquired over three 
cardiac cycles with care taken to ensure parallel cur-
sor alignment to flow and to adjust scale and filters to 
optimize the spectral Doppler tracings. Mitral valve 
(MV) E and A wave peak velocities, E-wave decelera-
tion times and A wave duration were measured in the 
apical four-chamber view with a 2  mm sample volume 
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placed at the tips of the MV leaflets. Isovolumic relaxa-
tion time was measured in the apical five-chamber view. 
Pulmonary vein S and D wave velocities were measured 
in the right pulmonary vein. LV myocardial performance 
index was calculated 
(
MV closure to opening time − 
LV ejection time
)/
LV ejection time . MV closure to 
opening time was measured in the apical four-chamber 
view, as the time from the cessation of the A wave to the 
onset of the E wave of MV inflow. LV ejection time was 
measured in the apical five-chamber view with a 2  mm 
sample volume placed immediately below the aortic valve 
annulus, as the time from the onset to cessation of LV out-
flow. LV stroke volume was estimated using the LV out-
flow cross-sectional area calculated from the dimension 
measured in the parasternal long-axis view multiplied by 
the LV outflow velocity time integral determined from the 
LV outflow pulse wave Doppler spectral tracing in the api-
cal five-chamber view. Cardiac output was estimated as 
stroke volume multiplied by heart rate.
Pulse tissue Doppler images were acquired over three car-
diac cycles from the apical four-chamber view with a 5 mm 
sample volume placed just below the lateral and septal MV 
annulus. MV lateral and septal e’, a’ and s’ tissue velocities 
were measured and the E/e’-ratios were calculated.
Myocardial deformation was assessed by measur-
ing LV mid circumferential strain, global longitudinal 
strain, basal and apical rotation and torsion. Grey-scale 
images acquired at frame rates between 40 and 90 frames 
per second were optimized for off-line speckle track-
ing analysis. Images acquired at the basal, mid and api-
cal ventricular levels in the parasternal short-axis view 
were used for assessment of circumferential strain, rota-
tion and torsion, and in the apical four-chamber view for 
assessment of longitudinal strain. The grey-scale images 
were analyzed offline on the EchoPAC software (General 
Electric, Milwaukee, WI, USA). The endocardial bor-
der was manually traced (starting at the mid-septum for 
short axis images and the basal septum from the apical 
four chamber images). Tracking was automatically per-
formed and the analysis was accepted after visual inspec-
tion and when the software indicated adequate tracking 
or retraced with manual adjustments. Circumferential 
strain curves from the mid ventricular level in the par-
asternal short-axis view were analysed to determine mid 
circumferential strain. Longitudinal strain curves from 
the apical four-chamber view were analysed for six seg-
ments (basal septum, mid septum, apical septum, api-
cal lateral, mid lateral and basal lateral) to determine 
the global longitudinal strain. Only image acquisitions 
with a minimum of four appropriately tracking segments 
were accepted for analysis. LV rotation was calculated by 
analysis at the basal and apical levels in the parasternal 
short-axis and torsion calculated as the peak instanta-
neous end-systolic difference between apical and basal 
rotation.
Assessment of endothelial function and arterial stiffness
Vascular assessments were conducted after 10 min of rest 
in the supine position, in a 25 °C temperature-controlled, 
quiet room. Measurements were taken at approximately 
0900 h in the fasted state. Peripheral blood pressure was 
measured in the right brachial artery with an automated 
DINAMAP® sphygmomanometer (Critikon, Tampa, 
Florida, USA) [25]. Conduit artery endothelial function 
was determined by recording diameter changes in the 
brachial artery in response to increased blood flow gen-
erated during reactive hyperemia, flow-mediated dilata-
tion (FMD) [25, 26]. Briefly, the right brachial artery was 
scanned 2–5  cm above the antecubital fossa using high 
resolution B-mode vascular ultrasound (Vivid 7 ultra-
sound machine, 7–15 MHz linear-array transducer). Lon-
gitudinal, ECG-gated, end-diastolic images were acquired 
and the brachial arterial diameter was determined for 
each image using automatic edge-detection software 
(Vascular Tools, Coralville, IA). Images were recorded 
for 1 min before a pressure cuff, around the forearm dis-
tal to the elbow, was inflated to >200 mmHg for 5 min. 
After cuff deflation, the increase in blood flow was meas-
ured (reactive hyperemia) along with the change in ves-
sel diameter (endothelium-dependent dilatation), which 
was measured for a further 5 min. FMD  % changes were 
defined as the maximal percentage changes in vessel 
diameter after reactive hyperemia as we have previously 
described [25, 26]. The variability for repeated measure-
ments of arterial diameters at flow mediated vasodila-
tation was 0.26  ±  0.01  % (% absolute value of brachial 
artery at FMD), which is similar to previous report [27].
Arterial stiffness was also assessed using pulse wave 
velocity (PWV) by sequentially recording ECG-gated 
right carotid and radial artery waveforms (carotid-
radial PWV), as well as right carotid and femoral artery 
(carotid–femoral PWV) waveforms (SPC-301, Mil-
lar Instruments SphygmoCor, AtCor Medical Systems 
Inc., Sydney, Australia). Two vascular measurements 
were obtained for each parameter and the average 
value reported. The use of the SphygmoCor device to 
assess arterial stiffness parameters has been previously 
published by our group [28]. Automated blood pres-
sure measurements were obtained using a DINAMAP 
machine (Critikon, Tampa, Florida) and the average of 
two values obtained immediately prior to the arterial 
stiffness assessments are reported.
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Statistical analysis
Data are summarized as mean  ±  SD unless otherwise 
specified. Comparisons between groups were performed 
using χ2 or Fisher’s exact test for categorical variables 
and unpaired Student’s t tests or analysis of variance for 
continuous variables. We used linear regression to assess 
adjusted relationship between echocardiographic meas-
ures and potential explanatory clinical variables adjust-
ing for age, gender, SBP, DBP, HbA1c, ACR, LDL, and 
BMI. Statistical significance was considered at p  <  0.05 
and we used the false discovery rate (FDR) method to 
control for the multiple testing. All statistical analysis 
was carried out using SAS 9.4 (SAS Institute, Cary, NC, 
USA).
Results
Baseline clinical characteristics
We compared 199 adolescents with T1D [median dis-
ease duration 6.2 (2.0–12.8) years] with all 178 healthy 
control subjects. These groups were well matched for 
sex, age and height (see Table 1), but T1D were heavier 
with larger BSA and body mass index (BMI). T1D had 
increased systolic and diastolic blood pressures (see 
Fig. 1), but only diastolic blood pressure remained signif-
icantly different when converted to z-scores for height. 
In the diabetes cohort, more participants were insulin 
pumper users (Table  1). The proportion of participants 
who had smoked cigarettes in the past or were current 
smokers is shown in Table 1 (p = 0.45 for between group 
difference in rate of smoking in T1D vs. the control 
group).
Endothelial function and arterial stiffness in the T1D 
and healthy control cohorts
Endothelial function as assessed by FMD was signifi-
cantly lower in the T1D compared to the healthy con-
trol group (6.45 ±  3.15 vs. 7.52 ±  3.20 %, p =  0.0015). 
For arterial stiffness, carotid-radial PWV was signifi-
cantly higher in T1D vs. healthy controls (7.28  ±  0.96 
vs. 6.89  ±  1.11  m/s, p  =  0.0015). Similar trends were 
seen for carotid-femoral PWV, although differences did 
not reach significance (5.25 ± 0.75 vs. 5.10 ± 0.87 m/s, 
p = 0.073).
Relationships of endothelial function and arterial stiffness 
with clinical data
Male gender was the only variable that explained a pro-
portion of the difference in FMD, between the T1D 
and control groups (β = −1.13 ± 0.43, p = 0.0132). For 
carotid-radial PWV, the variables that explained differ-
ences between the T1D and control groups were diastolic 
blood pressure (β = 0.056 ± 0.010, p = 0.0002) and male 
gender (β = 0.307 ± 0.123, p = 0.0138).
Echocardiographic assessment in the T1D and healthy 
control cohorts
Echocardiographic assessment adjusted for sex, age and 
BSA to accommodate for any differences in body pro-
portions between the groups are presented in Table  2; 
Fig. 1. Using M-mode echocardiography, smaller LV end-
systolic dimension and higher shortening fraction and 
ejection fraction were present in T1D compared with 
controls. Based on pulsed wave Doppler assessment of 
mitral inflow and pulmonary venous flow, isovolumic 
relaxation time was higher in T1D vs. control partici-
pants, but there were no other significant differences in 
T1D compared with controls. By pulsed wave tissue Dop-
pler assessment, T1D had significantly lower MV lateral 
and septal e’ and a’ and septal e’ myocardial velocities and 
higher E/e’ ratios. By myocardial deformation imaging, 
T1D had lower LV global longitudinal strain and higher 
mid circumferential strain, suggesting lower longitudinal, 
but higher circumferential function. Apical rotation and 
torsion were both higher in the T1D, while basal rotation 
did not differ.
Relationships of echocardiographic with clinical data
As shown in Table  3, age and blood pressure were the 
most common factors that contributed to differences in 
echocardiographic parameters between the T1D and 
control groups. In addition, body mass index (kg/m2) 
accounted in part for between group differences in left 
ventricular mean velocity of circumferential shorten-
ing and mitral valve lateral a’ wave tissue velocity. Low 
density lipoprotein (mmol/L) was also associated with 
between group differences in isovolumic relaxation time 
and mitral valve lateral s’ wave tissue velocity, and male 
gender was associated with between group differences 
for mitral valve lateral e’ wave tissue velocity and mitral 
valve E/lateral e’ ratio (Table 3).
Discussion
During childhood, patients with T1D generally do not 
have clinical cardiovascular symptoms as there is a delay 
between the diagnosis of T1D and cardiovascular events 
which could be used for therapeutic interventions slow-
ing down the progression of CV disease [8, 9, 29, 30]. 
Previous echocardiographic studies have shown vari-
able differences in left ventricular (LV) geometry, mass 
and function [10–15]. Recent data have suggested that 
myocardial deformation imaging may be able to detect 
changes in myocardial mechanical properties prior to 
changes in ejection fraction in children and adolescents 
with T1D [16]. In addition, measures of early peripheral 
vascular dysfunction such as FMD and arterial stiffness 
have been associated with adverse long-term outcomes 
in adults with type 2 diabetes [31]. It is important to 
Page 5 of 12Bradley et al. Cardiovasc Diabetol  (2016) 15:31 
carefully characterize early changes in cardiac and 
peripheral vascular function in an adequately powered 
cohort of young patients with T1D to better understand 
factors that may predispose adverse long term outcomes 
in adulthood [6]. Our major findings were that compared 
to a matched group of healthy controls, adolescents with 
T1D exhibit: (1) higher blood pressure; (2) impaired 
endothelial function and increased arterial stiffness and; 
(3) altered myocardial velocities and strain.
Our first major observation was that we found 
increased systolic and diastolic blood pressures in adoles-
cents with T1D compared with controls. Previous studies 
have consistently shown similar differences in blood pres-
sure in children and young adults with T1D compared 
with controls [10, 32, 33]. The modest blood pressure ele-
vation reported in otherwise healthy T1D cohorts would 
be silent clinically and has been previously reported to be 
associated with HbA1c [34], although we did not see such 
Table 1 Clinical measurements of adolescents with type 1 diabetes versus all controls
Blood work, smoking status data were available for a subgroup of n = 63 controls
Data are mean ± SD. BSA body surface area, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, MBP mean blood pressure, PP pulse 
pressure, HR heart rate, PP pulse pressure, HR heart rate, HbA1c haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein cholesterol, eGFR 
estimated glomerular filtration rate
Type 1 diabetes n = 199 All controls n = 178 p value
Sex (male:female) 98:101 84:94 0.69
Age (years) 14.4 ± 1.6 14.4 ± 2.1 0.80
Height (cm) 163 ± 10 162 ± 11 0.25
Weight (kg) 60.7 ± 14.3 54.7 ± 13.8 <0.0001
BSA (m2) 1.65 ± 0.22 1.57 ± 0.23 0.0006
Insulin administration (%)
 Pump 60.8 –
 Multiple injections 30.2 –
Smoking status n (%)
 Never smoked 181 (92.8) 63 (100)
 Smoked few puffs to a whole cigarette in my life 9 (4.6) 0
 Only 2 to 3 cigarettes in my life 1 (0.5) 0
 More than 3, but fewer than 100 cigarettes in my life 1 (0.5) 0
 >100 cigarettes in my life, none in the past month 1 (0.5) 0
 >100 cigarettes in my life, some in the last month but not every day 1 (0.5) 0
 >100 cigarettes in my life, at least 1 cigarette every day during the last month 2 [1] 0
BMI (kg/m2) 22.6 ± 4.3 20.6 ± 3.7 <0.0001
SBP (mmHg) 113 ± 10 110 ± 9 0.0005
SBP z-score for height 0.2 ± 0.9 −0.1 ± 0.9 0.0011
DBP (mmHg) 62 ± 7 58 ± 7 <0.0001
DBP z-score for height −0.3 ± 0.6 −0.6 ± 0.7 <0.0001
MBP (mmHg) 77 ± 7 75 ± 7 0.0053
PP (mmHg) 51 ± 9 52 ± 8 0.48
HR (bpm) 66 ± 9 68 ± 12 0.036
Diabetes duration (years) 7.2 ± 3.1 – −
Glucose (mmol/l) 9.7 ± 4.4 4.7 ± 0.7 <0.0001
HbA1c (%) 0.085 ± 0.012 0.054 ± 0.002 <0.0001
HbA1c mmol/mol 84.9 ± 12.4 53.8 ± 2.4 <0.0001
Cholesterol (mmol/L) 4.3 ± 0.88 4.24 ± 0.83 0.5158
HDL cholesterol (mmol/L) 1.6 ± 0.36 1.46 ± 0.28 0.0004
LDL cholesterol (mmol/L) 2.3 ± 0.71 2.36 ± 0.74 0.6109
Triglycerides (mmol/L) 0.84 ± 0.37 0.93 ± 0.40 0.0945
Creatinine (mmol/L) 54 ± 9 56 ± 11 0.1149
eGFR (mL/min/1.73 m2) 113 ± 17 108 ± 17 0.0405
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as relationship in this cohort (Spearman coefficient for 
HbA1c and SBP: −0.02, p = 0.75 and for DBP r = 0.11, 
p  =  0.12). Nevertheless, similar blood pressure eleva-
tions within the “normal range” are important due to the 
increased risk of microalbuminuria and retinopathy asso-
ciated with these changes [35, 36], as well as the potential 
impact on future cardiovascular risk [10, 32, 33, 37–39]. 
Furthermore, recent meta-analyses have suggested that 
even small reductions in blood pressure have a benefit on 
cardiovascular events, highlighting the potential impor-
tance of identifying and characterizing early changes in 
blood pressure, even within the normal range [40].
From a physiologic perspective, it seems unlikely that 
higher blood pressure in the T1D group was due to pri-
mary changes in cardiac function, since between group dif-
ferences in mean heart rate, LV stroke volume and ejection 
fraction or cardiac output were very small. Instead, based 
on abnormalities described below, it seems more plausible 
that the higher blood pressure values may therefore have 
been due to an increase in peripheral vascular resistance, 
thereby leading to secondary echocardiographic changes. 
An increase in peripheral vascular resistance as the primary 
cause of early increases in blood pressure in T1D, rather 
than an increase in cardiac output, would be in contrast 
Fig. 1 Box and whisker plots of significant group differences in blood pressure and echocardiographic measurements between adolescents with 
type 1 diabetes and controls. Boxes represent inter-quartile ranges (IQR), the ends of the whisker are set at 1.5* IQR above the third quartile and 1.5* 
IQR below the first quartile, and the minimum or maximum outliers are only shown if outside this range
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with early blood pressure changes in young, non-diabetic 
patients with essential hypertension. In this non-diabetic 
setting, increased cardiac output has been reported as 
the earliest hemodynamic change that precedes a rise in 
peripheral vascular resistance [41]. Fortunately, partici-
pants in the AdDIT study will be assessed longitudinally 
after the end of the initial study phase. As such, the natu-
ral history of early blood pressure abnormalities in patients 
with T1D will be determined in future follow up studies.
In addition to measuring blood pressure, to more 
fully evaluate the peripheral vasculature, we evaluated 
endothelial function with FMD and arterial stiffness using 
PWV [42], since peripheral vascular abnormalities have 
been associated with the development of clinical hyper-
tension and future cardiovascular complications [31, 43, 
44]. Previous studies have demonstrated abnormalities in 
vascular function in children with T1D, although these 
studies have, for the most part, been limited by small 
Table 2 Echocardiographic measurements of adolescents with type 1 diabetes versus all controls
Data are mean ± SD
IVS interventricular septal, LV left ventricular, MV mitral valve
* Adjusted for sex, age, BSA and for multiple comparisons
Type 1 diabetes n = 199 All controls n = 178 p value*
M-mode
 IVS thickness in diastole (cm) 0.74 ± 0.12 0.73 ± 0.12 0.43
 LV end-diastolic dimension (cm) 4.69 ± 0.39 4.66 ± 0.43 0.09
 LV end-systolic dimension (cm) 2.90 ± 0.32 2.95 ± 0.33 0.0032
 LV posterior wall thickness in diastole (cm) 0.66 ± 0.11 0.64 ± 0.11 0.72
 LV mass indexed (g/m2) 63 ± 13 63 ± 13 0.32
 LV shortening fraction (%) 38 ± 4 37 ± 4 0.012
 LV ejection fraction (%) 68 ± 5 66 ± 5 0.008
 LV mean velocity of circumferential shortening (circ/sec) 1.18 ± 0.18 1.14 ± 0.16 0.075
Pulse doppler
 MV E wave velocity (cm/s) 100 ± 15 99 ± 17 0.81
 MV A wave velocity (cm/s) 41 ± 9 42 ± 11 0.58
 MV E/A ratio 2.5 ± 0.7 2.5 ± 0.7 0.75
 MV A wave duration (msec) 122 ± 18 119 ± 20 0.36
 MV deceleration time (msec) 154 ± 17 149 ± 20 0.075
 Isovolumic relaxation time (msec) 76 ± 8 74 ± 7 0.038
 Pulmonary vein S wave velocity (cm/s) 41 ± 10 43 ± 11 0.084
 Pulmonary vein D wave velocity (cm/s) 61 ± 10 61 ± 12 0.89
 LV myocardial performance index 0.30 ± 0.10 0.30 ± 0.09 0.82
 LV stroke volume (ml) 70 ± 18 66 ± 17 0.72
 LV cardiac output (l/min) 4.6 ± 1.2 4.4 ± 1.2 0.53
Tissue doppler
 MV lateral e’ wave tissue velocity (cm/s) 17.6 ± 2.6 18.6 ± 2.6 0.0003
 MV lateral a’ wave tissue velocity (cm/s) 5.4 ± 1.1 5.9 ± 1.5 0.0003
 MV lateral s’ wave tissue velocity (cm/s) 10.5 ± 1.8 11.1 ± 2.0 0.0005
 MV E/lateral e’ ratio 5.8 ± 1.1 5.4 ± 1.0 0.001
 MV septal e’ wave tissue velocity (cm/s) 13.9 ± 1.8 15.1 ± 2.2 0.0003
 MV septal a’ wave tissue velocity (cm/s) 5.5 ± 1.0 5.9 ± 1.3 0.0008
 MV septal s’ wave tissue velocity (cm/s) 8.3 ± 0.9 8.6 ± 0.9 0.001
 MV E/septal e’ ratio 7.3 ± 1.2 6.7 ± 1.3 0.0003
Myocardial deformation
 LV mid circumferential strain (%) −20.4 ± 2.3 −19.5 ± 1.7 0.0003
 LV global longitudinal strain (%) −19.0 ± 1.9 −19.8 ± 1.5 0.0003
 Basal rotation (degrees) −4.2 ± 2.4 −4.2 ± 2.0 0.89
 Apical rotation (degrees) 6.2 ± 3.0 5.4 ± 2.5 0.009
 Torsion (degrees) 10.4 ± 3.6 9.5 ± 3.0 0.026
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sample sizes [45], by differences in gender distributions 
[4, 46], by the lack of inclusion of HC [47], and by the 
inclusion of patients with T1D with children who have 
other conditions such as hypercholesterolemia [48]. Our 
second major observation was that in this well-defined, 
large cohort of adolescents, those with T1D exhibited 
impaired endothelial function with lower FMD and 
increased arterial stiffness as higher carotid-radial PWV. 
In contrast with a previous smaller study (n = 28), simi-
lar trends for carotid-femoral PWV did not reach signifi-
cance [46]. Interestingly, in a multivariate analysis aimed 
at elucidating the specific factors underlying between 
group differences in vascular function, male gender had a 
negative impact on measures of endothelial function and 
arterial stiffness. In previous work, we and others have 
reported that adult women with T1D have higher arte-
rial stiffness compared to men [49]. While sex hormone 
influences on autonomic function [50] and microvascular 
complications [51] have been reported elsewhere, this is 
to our knowledge, the first report documenting a poten-
tial role for gender as a modifier of arterial stiffness in 
adolescents with T1D. In the current analysis, although 
positive associations between PWV and BMI and PWV 
and blood pressure were perhaps expected [2], the asso-
ciation between male gender and higher PWV was sur-
prising, and suggests that relationship gender and arterial 
stiffness changes in relation to pubertal status, a possibil-
ity that has been reported elsewhere and that requires 
further study [52]. Previous studies also have shown that 
in women FMD is higher when compared to men [53]. 
Less, however, is known about gender and FMD in ado-
lescents. The current analysis suggests that as in adults, 
male gender has a negative effect on vascular function 
in adolescents. However, in our large cohort of patients 
with T1D and in contrast with previous work [46], the 
overall magnitude of the effect of T1D on arterial stiff-
ness appears to be modest.
Our third major finding relates to changes in LV sys-
tolic and diastolic function in adolescents with T1D. 
Increased measures of LV systolic function by M-mode, 
Table 3 Determinants of differences in echocardiographic 
parameters in type 1 diabetes and control participants
Beta estimate p value
LV end-systolic dimension (cm)
 Age (years) 0.0564 0.0003
 Body mass index (kg/m2) 0.0155 0.005
 Male gender 0.1278 0.003
LV shortening fraction (%)
 Systolic blood pressure (mmHg) 0.105 0.006
 Age (years) −0.562 0.0015
LV ejection fraction (%)
 Systolic blood pressure (mmHg) 0.130 0.006
 Age (years) −0.752 0.0003
LV mean velocity of circumferential shortening (circ/sec)
 Age (years) −0.016 0.015
 Body mass index (kg/m2) 0.007 0.021
Isovolumic relaxation time (msec)
 Age (years) 0.995 0.002
 Low density lipoprotein (mmol/L) 1.399 0.045
 MV lateral e’ wave tissue velocity (cm/s)
 Systolic blood pressure (mmHg) 0.05489 0.015
 Diastolic blood pressure (mmHg) −0.1192 0.0003
 Male gender −0.8703 0.015
MV lateral a’ wave tissue velocity (cm/s)
 Age (years) −0.09277 0.036
 Body mass index (kg/m2) 0.04254 0.036
MV lateral S’ wave tissue velocity (cm/s)
 Systolic blood pressure (mmHg) 0.05823 0.0003
 Diastolic blood pressure (mmHg) −0.06427 0.003
 Low density lipoprotein (mmol/L) −0.3702 0.022
MV E/lateral e’ ratio
 Male gender 0.4664 0.003
MV septal e’ wave tissue velocity (cm/s)
 Systolic blood pressure (mmHg) 0.0395 0.015
 Diastolic blood pressure (mmHg) −0.067 0.003
 Low density lipoprotein (mmol/L) −0.531 0.004
 Body mass index (kg/m2) −0.0804 0.015
MV septal a’ wave tissue velocity (cm/s)
 Age (years) 0.0876 0.021
 Body mass index (kg/m2) 0.0460 0.011
MV septal s’ wave tissue velocity (cm/s)
 Systolic blood pressure (mmHg) 0.034 0.0003
 Diastolic blood pressure (mmHg) −0.036 0.0003
 Age (years) −0.0778 0.016
 Albumin to creatinine ratio (mg/mmol) −0.0714 0.004
 Low density lipoprotein (mmol/L) −0.293 0.0006
 Body mass index (kg/m2) 0.0289 0.041
MV E/septal e’ ratio
 Age (years) −0.1276 0.011
LV mid circumferential strain (%)
 Systolic blood pressure (mmHg) −0.0677 0.020
LV left ventricular, MV mitral valve
Table 3 continued
Beta estimate p value
 Age (years) 0.2991 0.021
 Male gender 1.0854 0.019
LV global longitudinal strain (%)
 Age (years) 0.1788 0.011
 Male gender 0.4800 0.041
 Apical rotation (degrees) N/A N/A
 Torsion (degrees) N/A N/A
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such as shortening and ejection fraction as we found in 
our cohort, suggest that LV systolic function at rest is 
increased in adolescents with T1D. These observations 
have been suggested by others in a small (n = 39) adoles-
cent cohort that only included boys, although the mecha-
nism is not well understood [10]. Early changes in LV 
diastolic dysfunction found in our cohort, as indicated 
by longer isovolumic relaxation times, suggest differ-
ences in early relaxation and have been shown in previ-
ous small adolescent cohort studies [14, 15]. Similarly we 
found evidence by tissue Doppler assessment of changes 
in LV diastolic function with lower mitral valve lateral 
and septal myocardial velocities and higher mitral valve 
E/e’ ratios. Similar to observed changes in LV posterior 
wall thickness suggesting early LV hypertrophic changes, 
it is tempting to link changes in diastolic function to 
the higher blood pressure values within the “normal” 
range observed in this cohort. However, we recognize 
that other factors, such as activation of neurohormo-
nal systems including the sympathetic nervous system 
or renin-angiotensin-aldosterone system, or deposition 
of advanced glycation end-products [54] may also be 
involved and could cause both higher blood pressure and 
ventricular remodeling.
In addition to these changes in M-mode echocardi-
ography, we observed early changes in LV myocardial 
velocities and strain in adolescents with T1D compared 
with controls. We speculate again that the higher blood 
pressure values observed in this T1D cohort, although 
still within the “normal” range, may in part explain this 
ventricular remodeling. Alteration of LV longitudinal 
deformation with decreased global longitudinal strain, 
similar to what we found in our cohort, has been previ-
ously reported in children and adults with T1D [16, 55]. 
LV global longitudinal strain plays an important role in 
cardiac pump function and is primarily controlled by 
subendocardial longitudinal myofibres, which are more 
susceptible to afterload [16, 56]. Consequently, subclini-
cal impairment in LV longitudinal deformation has been 
observed in the setting of many conditions associated 
with increased afterload or chronic pressure loading 
including hypertension and aortic stenosis [57, 58]. The 
increased LV mid circumferential strain we found may be 
an adaptive response to the decreased global longitudinal 
strain, as previously suggested in studies where radial and 
longitudinal contractility parameters have been meas-
ured in adults with T1D [55].
Our observations have potential clinical implications 
for the early identification of patients with T1D who are 
at high risk of future complications, and for earlier thera-
peutic interventions. FMD and arterial stiffness measures 
have been shown to predict future cardiovascular events 
in high risk groups, although the clinical utility of these 
parameters in early T1D has yet to be determined [31, 
44]. The careful physiological phenotyping performed as 
part of our longitudinal observational study will there-
fore be important to determine if preclinical changes in 
cardiovascular function reported are associated with 
new onset hypertension, albuminuria, eGFR decline or 
even cardiovascular events in this cohort. Compared to 
previous cohorts involving adolescents with T1D, this 
dataset is unique, due to the longitudinal follow up that 
is planned in a subset of patients, and because findings 
form this observational, pilot cohort may be used to iden-
tify cardiovascular parameters of interest that could be 
modified by ACE inhibition/statin therapies being using 
in the separate cohort of participants currently enrolled 
in the AdDIT interventional study. On the therapeutic 
side, abnormalities in peripheral vascular function can be 
ameliorated with renal and cardiovascular protective and 
glucose lowering agents [26, 59]. Although the magni-
tude of the overall differences was small, it is potentially 
important to better understand early measures of car-
diovascular dysfunction to potentially identify and treat 
high risk patients with T1D and thereby avoid end organ 
complications.
Our work has important limitations. Our adolescents 
with T1D were well matched in comparison to our con-
trols, except for being heavier with consequent larger 
BSA and BMI. To account for these differences, we addi-
tionally reported models adjusted for sex, age and BSA. 
BSA was chosen, given that echocardiographic param-
eters are routinely indexed to this rather than BMI. Sec-
ond, despite our relatively large sample size, we found 
only carotid-radial PWV and not carotid–femoral PWV 
differed between the two groups. Since carotid-femoral 
PWV is thought to reflect larger arteries compared to 
carotid-radial PWV, it is possible that early changes in 
arterial stiffness in adolescents with T1D are primar-
ily limited to smaller arteries. Given the cross sectional 
design of this analysis, we were not able to determine the 
long term clinical significance of this and other statisti-
cally significant between group differences. Longitudinal 
data is being collected in this cohort as part of the AdDIT 
Observational Study and will help to clarify the relation-
ships between these physiological measures and clini-
cal outcomes. Finally, this study in adolescents was not 
designed to elucidate physiological mechanisms respon-
sible for between group differences in cardiovascular 
function, such as early changes in nitric oxide bioavail-
ability, autonomic tone, vitamin D levels or inflammatory 
biomarkers [60–63]. These important modulators of car-
diovascular function should be further examined in ado-
lescents in future work. Similarly, potential physiological 
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factors that determine cardiovascular risk within the ado-
lescent cohort such as the impact of glycemic variabil-
ity—require further dedicated studies [64].
In conclusion, adolescents with T1D exhibit early 
changes in blood pressure, peripheral vascular function 
and left ventricular myocardial deformation indices with 
a shift from longitudinal to circumferential shortening. 
Longitudinal follow-up of these changes may allow early 
detection of those most at risk of early adult-onset car-
diac disease that would preferentially benefit from pre-
ventive therapeutic interventions. Additional studies are 
also required to better elucidate subgroups of patients 
with early T1D with the most deleterious cardiovascu-
lar profiles, who may, as a consequence, be at the highest 
risk of future clinical disease.
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